The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia

Carolin Rommel, Stephan Rösner, Achim Lother, Margareta Barg, Martin Schwaderer, Ralf Gilsbach, Timo Bönicke, Tilman Schnick, Sandra Mayer, Sophia Doll, Michael Hesse, Oliver Kretz, Brigitte Stiller, Franz-Josef Neumann, Matthias Mann, Markus Krane, Bernd K. Fleischmann, Ursula Ravens, Lutz Hein

Rationale: Structural and electrophysiological remodeling of the atria are recognized consequences of sustained atrial arrhythmias, such as atrial fibrillation. The identification of underlying key molecules and signaling pathways has been challenging because of the changing cell type composition during structural remodeling of the atria.

Objective: Thus, the aims of our study were (1) to search for transcription factors and downstream target genes, which are involved in atrial structural remodeling, (2) to characterize the significance of the transcription factor ETV1 (E twenty-six variant 1) in atrial remodeling and arrhythmia, and (3) to identify ETV1-dependent gene regulatory networks in atrial cardiac myocytes.

Methods and Results: The transcription factor ETV1 was significantly upregulated in atrial tissue from patients with permanent atrial fibrillation. Mice with cardiac myocyte-specific overexpression of ETV1 under control of the myosin heavy chain promoter developed atrial dilatation, fibrosis, thrombosis, and arrhythmia. Cardiac myocyte-specific ablation of ETV1 in mice did not alter cardiac structure and function at baseline. Treatment with Ang II (angiotensin II) for 2 weeks elicited atrial remodeling and fibrosis in control, but not in ETV1-deficient mice. To identify ETV1-regulated genes, cardiac myocytes were isolated and purified from mouse atrial tissue. Active cis-regulatory elements in mouse atrial cardiac myocytes were identified by chromatin accessibility (assay for transposase-accessible chromatin sequencing) and the active chromatin modification H3K27ac (chromatin immunoprecipitation sequencing). One hundred seventy-eight genes regulated by Ang II in an ETV1-dependent manner were associated with active cis-regulatory elements containing ETV1-binding sites. Various genes involved in Ca²⁺ handling or gap junction formation (Ryr2, Jph2, Gja5), potassium channels (Kcnh2, Kcnk3), and genes implicated in atrial fibrillation (Tbx5) were part of this ETV1-driven gene regulatory network. The atrial ETV1-dependent transcriptome in mice showed a significant overlap with the human atrial proteome of patients with permanent atrial fibrillation.

Conclusions: This study identifies ETV1 as an important component in the pathophysiology of atrial remodeling associated with atrial arrhythmias. (Circ Res. 2018;123:550-563. DOI: 10.1161/CIRCRESAHA.118.313036.)

Key Words: angiotensin II • atrial fibrillation • fibrosis • transcription factor • transcriptome

Multiple factors contribute to the development and progression of atrial fibrillation (AF). Structural and electrophysiological remodeling of the atria are recognized consequences of sustained atrial arrhythmias, such as AF. Atrial structural remodeling is characterized by fibrosis, atrial dilatation, and cardiac myocyte hypertrophy resulting in electrical disturbances and perpetuation of AF. Electrical and structural alterations result in stasis of blood and a prothrombotic state increasing the risk of ischemic stroke.

Editorial, see p 515
In This Issue, see p 507
Meet the First Author, see p 508

In May 2018, the average time from submission to first decision for all original research papers submitted to Circulation Research was 13.37 days.

From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (C.R., S.R., A.L., M.B., M.S., R.G., T.B., T.S., M.H., B.K.F.), Heart Center, Congenital Heart Defects and Pediatric Cardiology, Faculty of Medicine (T.S., B.S.), Medicine, Renal Division, Medical Faculty, University of Bonn, Germany (M.H., B.K.F.); III, Medicine, University Medical Center Hamburg-Eppendorf, Germany (O.K.); Cardiovascular Surgery, German Heart Center Munich at the Technische Universität München, Germany (M.K.); INSURE (Institute for Translational Cardiac Surgery), Cardiovascular Surgery, Munich, Germany (M.K.); DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (M.K.); Institute of Experimental Cardiovascular Medicine, University Heart Center Freiburg-Bad Krozingen, Germany (U.R.); Pharmacology and Toxicology, Medical Faculty, Technische Universität Dresden, Germany (U.R.); and Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (S.D., M.M.).

The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.118.313036. Correspondence to Lutz Hein, MD, Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Albertstrasse 25, 79104 Freiburg, Germany, Email lutz.hein@pharmakol.uni-freiburg.de

© 2018 American Heart Association, Inc.
Atrial fibrillation is accompanied by changes in atrial wall structure, cell composition, and extracellular matrix deposition. Identification of molecular signaling pathways involved in this atrial remodeling has been challenging because of the changing cellular composition of atria. We identified upregulation of the transcription factor ETV1 (E twenty-six variant 1) mRNA and protein in atrial tissue from patients with permanent atrial fibrillation. To determine functional significance of ETV1 in atrial cardiac myocytes, we generated mice with cell type–specific overexpression or ablation of ETV1. Overexpression of ETV1 in cardiac myocytes led to atrial enlargement, atrial fibrosis, thrombosis, and arrhythmia. In contrast, ETV1 knockout prevented atrial remodeling induced by chronic infusion of angiotensin II. To identify target genes that are regulated by angiotensin II in an ETV1-dependent manner, we isolated cardiac myocytes or their nuclei from mouse atria and RNA expression and open chromatin patterns were analyzed by next-generation sequencing. We identified >170 target genes of ETV1, including several genes involved in electrophysiological and hypertrophic remodeling of atrial myocytes. This network of ETV1-dependent genes in mouse atria was similar to the proteome signature of human atria in permanent atrial fibrillation. The findings provide insights into the molecular mechanisms involved in the pathogenesis of atrial fibrillation.

Ang II (angiotensin II) and other signaling molecules, including TGF-β1 (transforming growth factor-β1), play an important role in atrial and ventricular remodeling of the heart. Increased Ang II levels and activation of intracellular signaling can be detected even before the development of atrial fibrillation. Ang II, the active mediator of the renin-angiotensin system, results from cleavage of Ang I by the angiotensin-converting enzyme and elicits its downstream effects via binding to the AT1R and AT2R (angiotensin receptors type 1 and 2). AT1R activation induces vasoconstriction, sodium and water retention, aldosterone and vasopressin release, stimulation of sympathetic tone, inflammation, fibrosis, and hypertrophy. Interestingly, mice with cardiac myocyte-specific overexpression of angiotensin-converting enzyme or AT1 receptors develop severe atrial dilatation and AF without overt changes in ventricular structure.

Many intracellular signaling pathways that coordinate the cardiac hypertrophic response are known. Ang II and catecholamines bind to GPCR (G-protein–coupled receptors) leading to the activation of different intracellular signaling pathways including MAPK (mitogen-activated protein kinases), intracellular Ca2+ release with activation of Ca2+-dependent cascades (eg, Ca2+/calmodulin-dependent protein kinase and calcineurin), or activation of protein kinase A. Ultimately, overactivity of these intracellular signaling pathways leads to activation or repression of cardiac myocyte transcription. Several transcription factors, including GATA (GATA-binding protein), MEF2 (myocyte enhancer factor 2), and the homeobox transcription factor NKX2.5 (NK2 homeobox 5) have been implicated in cardiac remodeling. However, less is known about transcription factors which are involved in atrial remodeling in chronic heart disease.

Thus, we searched for differential expression of transcription factors in human and mouse cardiac remodeling and identified ETV1 (E twenty-six variant 1) to be upregulated in cardiac atria from patients with AF. Our results demonstrate that cardiac myocyte-specific overexpression of ETV1 in the mouse induces atrial arrhythmia, atrial structural, and molecular remodeling. Furthermore, we identified active cis-regulatory regions in atrial cardiac myocytes and an ETV1-dependent gene regulatory network involved in atrial remodeling and arrhythmogenesis.

### Data Availability

The authors declare that all supporting data are available within the article and its Online Data Supplement. All sequencing data sets reported in this article are deposited in the Short Read Archive at the National Center for Biotechnology Information (NCBI) under the BioProject ID PRJNA470521.
human samples and PRJNA470522 for mouse data. Materials and further information are available upon personal request at the Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Germany.

**Human Cardiac Biopsies**

Investigations of cardiac biopsies were approved by the ethics committees of the University of Freiburg (Germany) and the Medical Faculty of the Technical University Dresden (ethical approval No. 15.1/01031/006/2008 and No. EK790799) and conform with the principles outlined in the Declaration of Helsinki.

**Animal Procedures**

All animal procedures were approved by the responsible Committee on the Ethics of Animal Experiments (Regierungspräsidium, Freiburg, Germany, permit numbers: G12/30 and G16/62), and they conformed to the Guide for the Care and Use of Laboratory Animals (2011).

**Generation of Mouse Models**

Transgenic mice overexpressing *Etv1* under control of the cardiac myocyte-specific α-myosin heavy chain promoter were generated by pronuclear injection (*Etv1*.camh). For the generation of cardiac myocyte-specific ETV1-deficient mice (*Etv1*mc) mice, carrying a floxed *Etv1* allele were crossed with ML2a-Cre (Cre recombinase expression under control of the myosin light chain [Myl7] promoter) mice.

**Ang II Stimulation In Vivo**

Micro-osmotic pumps were used for continuous subcutaneously delivery of 2 mg kg⁻¹ d⁻¹ Ang II for 14 days.

**Electrocardiography**

Electrocardiography was assessed in mice 1 week after birth during isoflurane anesthesia (2% Vol/ Vol in O₂). In adult mice, telemetry transmitters were implanted subcutaneously under isoflurane anesthesia (2% Vol/ Vol in O₂).

**Catheter Measurements**

Mice were anesthetized and after dissection of the right carotid artery a 1.4F pressure catheter was introduced into the left ventricle (LV).

**Histological Analysis**

For histological analysis, hearts were excised, fixed in paraformaldehyde solution, subsequently dehydrated, and embedded in paraffin and stained as described. To evaluate cardiac myocyte size, LV sections were stained with wheat germ agglutinin-Alexa Fluor 488 conjugate.

**Isolation of Atrial Cardiac Myocyte Nuclei**

Cardiac myocyte nuclei were isolated, stained with antibodies against phospholamban, and purified by fluorescence-assisted cell sorting as described previously.

**Isolation of Atrial and Ventricular Cardiac Myocytes**

Atrial and ventricular myocytes were enzymatically isolated by Langendorff perfusion followed by enzymatic digestion. Isolated atrial cardiac myocytes were picked individually under a microscope and processed for isolation of RNA.

**Gene Expression Analysis**

Total RNA from atria and ventricles was isolated with the RNeasy Mini Fibrous Tissue Kit. Five hundred nanograms of RNA was transcribed, and RT-qPCR (quantitative reverse transcription PCR) was performed. For RNA sequencing, libraries were generated and sequencing was performed on a HiSeq 2500 (50 bp; Illumina).

**Assay for Transposase-Accessible Chromatin Sequencing**

Isolated atrial cardiac myocyte nuclei were mixed with the transposition reaction mix (Nextera DNA Library Preparation Kit; Illumina) as described previously.

**Chromatin Immunoprecipitation Sequencing**

Chromatin was isolated from atrial cardiac myocytes (HL-1 cells) sheared by sonication, and isolated following the manufacturer's manual of the ChIP-IT High Sensitivity Kit (Active Motif). Two micrograms of chromatin and 4 μg of the antibody against H3K27ac (ab4729; Abcam) were used.

**General Bioinformatic Analysis**

Computational analysis of sequencing data was performed with tools integrated in the Galaxy platform. Sequencing reads were mapped with bowtie2 (chromatin immunoprecipitation sequencing [ChIP-seq], ATAC-seq [assay for transposase-accessible chromatin sequencing]) and RNA STAR (spliced transcripts alignment to a reference RNA-seq). Cuffdiff was used to assess differential gene expression. DeepTools were used for quality control, normalization, and genome-wide visualization. Peak identification was performed with MACS2 (model-based Analysis of ChIP-Seq 2; q<0.05).

**Human AF Proteome**

Mass spectrometry-based proteome data from patients with permanent AF were reanalyzed for this study. Details about sample preparation for mass spectrometry (MS) analysis, liquid chromatography-MS analysis, and MS data analysis are described in Doll et al.

**Statistics**

Data were displayed as mean±SEM. Student t test, 1-way, or 2-way ANOVA followed by Bonferroni post hoc test were used for statistical analysis of normally distributed data sets. Nonparametric Mann-Whitney test or Kruskal-Wallis ANOVA followed by Dunn post hoc test was performed for data sets without evidence for normal distribution. P values <0.05 were considered statistically significant.

**Results**

**ETV1 Is Upregulated in Human and Mouse Heart Disease**

During the search for genes differentially regulated in human heart disease, we found upregulation of the transcription factor ETV1 mRNA and protein in cardiac atria from patients with permanent AF (Figure 1A and 1B). As *Etv1* expression levels were 5-fold higher in atria than in ventricles (Figure 1C), we sought to further characterize the functional significance of ETV1 in atria. Expression of *Etv1* mRNA was higher in the free atrial wall when compared with the sinus node (Figure 1D), but it did not differ between left and right atria (Figure 1E).

**Cardiac Myocyte-Specific Overexpression of Etv1 Increases Mortality Rate**

To investigate the cardiac function of ETV1, we generated 2 genetically modified mouse models. First, transgenic mice overexpressing *Etv1* under control of the cardiac myocyte-specific α-MHC (α-myosin heavy chain gene) promoter (*Etv1*ahc) were generated by pronuclear injection (Figure 1F), and 2 independent transgenic lines were established which showed similar phenotypes. *Etv1* overexpression led to increased atrial and ventricular *Etv1* mRNA and ETV1 protein levels in transgenic mice (Figure 1G and 1H; Online Figure IA and IB). Surprisingly, *Etv1*ahc transgenic mice showed a significantly increased mortality rate compared with wild-type (WT) littermates (Figure 1I). *Etv1*ahc transgenic mice showed normal LV function and morphology when compared with WT littermates 12 weeks after birth (Online Figure IIA through IIG).
Overexpression of Etv1 Leads to Arrhythmia in Adult Etv1<sup>αMHC</sup> Mice

To further search for causes of premature death of Etv1<sup>αMHC</sup> mice, ECG was performed in mice 1 week after birth. At this time point, ECG analysis showed no differences between genotypes (Figure 2A). Next, ECG telemetry devices were implanted in adult mice (12 weeks; Figure 2F through 2J; Online Figures IIIA and IV). At this age, Etv1<sup>αMHC</sup> mice showed bradycardia and a loss of P waves (Figure 2F and 2G). Female (Figure 2F through 2J) and male (Online Figure IIIA and IIIB) Etv1<sup>αMHC</sup> mice showed the same phenotype. Compared with young mice, adult Etv1<sup>αMHC</sup> animals showed arrhythmias at 12 weeks of age (Figure 2K and 2L, Online Figures IIIB and IV). For analysis of arrhythmias, successive RR intervals were plotted against the immediately preceding RR intervals. WT mice showed a typical torpedo pattern associated with normal SR (Figure 2M), whereas adult Etv1<sup>αMHC</sup> mice displayed an island type A pattern which is typical for
Figure 2. Overexpression of the transcription factor ETV1 (E twenty-six variant 1) leads to arrhythmia in adult Etv1αMHC mice. A, Representative ECG recordings of wild-type (WT) (black) and Etv1αMHC transgenic mice (blue) 1 week after birth. B–E, Quantification of (B) heart rate, (C) QRS interval, (D) P-wave duration, and (E) PR interval (n=4–11). F, Representative ECG recordings of adult WT (black) and Etv1αMHC transgenic mice (blue). G–J, Quantification of (G) heart rate, (H) QRS interval, (I) P-wave duration, and (J) PR interval (n=6 per genotype; n.d., not detectable). K–N, Heart rhythm. K, Representative ECG recordings of WT (black) and Etv1αMHC transgenic mice (blue) 1 week after birth. L, Representative ECG recordings of adult WT and Etv1αMHC transgenic mice (12 weeks). There were no differences between the genotypes 1 week after birth. Adult Etv1αMHC transgenic mice showed arrhythmia. M, N, Lorenz (Poincaré) plot for analysis of heart rate variability. The duration of an RR interval (x axis) is plotted against the duration of the following RR interval (RR’; y axis). M, WT mice (black) showed a typical torpedo pattern associated with normal sinus rhythm. N, Etv1αMHC transgenic mice (blue) showed an island type A pattern associated with atrial arrhythmia. Mean±SEM; **P<0.01.
atrial arrhythmia (Figure 2N). Analysis of individual ECGs of 12-week-old mice showed loss of P waves in all transgenic mice (Figure 2F) with different ECG patterns in individual Etv1αMHC animals (Online Figure IVG through IVL). Although some mice showed regularly spaced RR intervals (Online Figure IVG and IVI), others had irregular RR intervals (Online Figure IVK) or varying morphology of QRS complexes (Online Figure IVH, IVJ, and IVL).

Etv1αMHC Mice Display Severe Atrial Remodeling

To determine whether atrial arrhythmia in Etv1αMHC mice was accompanied by structural changes, hearts were analyzed using morphological and histological approaches. Cardiac sections stained with hematoxylin and eosin from mice 1 week after birth showed no morphological differences between genotypes (Figure 3A). In contrast, adult Etv1αMHC mice displayed enlargement and dilatation of left and right atria (Figure 3B). Moreover, Etv1αMHC mice had an increased weight of left and right atria compared with WT animals (Figure 3C; Online Figure IIIC), and 4 out of 6 Etv1αMHC mice developed atrial thrombi by age of 12 weeks (Figure 3D). Interstitial fibrosis, identified by Sirius red staining, was strongly induced in Etv1αMHC atria (Figure 3E). Expression of vimentin (Vim) and the myofibroblast marker gene α-smooth muscle actin (Acta2) was increased in Etv1αMHC atria (Figure 3F). In addition, Western blot analysis of alcalasequenin, a major Ca2+-binding protein in the sarcoplasmic reticulum, was decreased in atria from Etv1αMHC mice (Figure 3G). Electron microscopy revealed significant structural remodeling of Etv1αMHC atria 12 weeks after birth, whereas WT atria showed a normal dense and organized sarcomere structure (Figure 3H and 3I; Online Figure V). Etv1αMHC atria were characterized by abundant fibroblasts, interstitial collagen fibers, and loss of cardiac myocyte interfibrillar mitochondria and sarcomere structure (Figure 3H and 3I; Online Figure V).

Both Etv1αMHC transgenic lines showed a similar phenotype with atrial remodeling and arrhythmia. Transgenic mice from line number 2 were characterized by a higher transgene copy number (Online Figure VIA) which was also accompanied by premature death. At the age of 17 to 33 weeks, Etv1αMHC animals displayed massive atrial enlargement and thrombi (Online Figure VIF). In these moribund mice, there were also reductions of LV contractility and relaxation (Online Figure VIC through VIE), likely because of obstruction of ventricular inflow and ineffective atrial emptying because of atrial arrhythmia.

Cardiac Myocyte-Specific Ablation of Etv1 Expression

To further determine the functional significance of ETV1 in the heart, mice with specific ablation of Etv1 in cardiac myocytes (Etv1MLCCre) were generated by breeding mice carrying a floxed Etv1 allele with MLC2a-Cre mice (Figure 4A). Exon 11 which encodes the ETS-binding domain was removed using the Cre/loxP system. Etv1 mRNA was significantly reduced in cardiac myocytes from Etv1MLCCre mice, whereas Etv1 expression was not changed in nonmyocytes (Figure 4B). Etv1MLCCre mice were viable and showed normal survival rates (Online Figure VIIA).

Ang II is known to play an important role in atrial remodeling and fibrillation; mice were treated with Ang II for 14 days via osmotic pumps. ECG analysis revealed no irregularities in Etv1MLCCre and control mice at baseline or after Ang II stimulation (Online Figure VIIIA through VIIIF). Heart rate, QRS interval, P-wave duration, and PR interval (Online Figure VIIIC through VIIF) were not different in Etv1MLCCre animals compared with control animals. Both genotypes showed regular SR at baseline and after Ang II stimulation (Online Figure VIIIG and VIIIH). In addition, Lorenz (Poincaré) plots from control and Etv1MLCCre animals displayed a toroid pattern associated with SR (Online Figure VIII and VIIIH).

LV contractile function, heart rate, and LV wall dimensions at baseline and after Ang II treatment did not differ between Etv1MLCCre and control mice (Online Figure IXA through IXF). LV morphology was similar between genotypes at baseline and after Ang II stimulation (Online Figure XA through XH). Ang II stimulation led to an increased connective tissue growth factor (Ctgf) expression in control and Etv1MLCCre ventricles (Online Figure XI).

Etv1 Knockout Mice Are Protected From Atrial Remodeling After Ang II Stimulation

Four-chamber sections stained with hematoxylin and eosin from adult Etv1MLCCre, and control mice showed no morphological differences between the genotypes (Figure 4C). Although Ang II stimulation did not affect atrial weight in both genotypes (Figure 4D), it caused severe atrial fibrosis in control but not in Etv1MLCCre mice (Figure 4E through 4G). Ang II stimulation induced mRNA expression of Vim in atria from control animals, although this upregulation was prevented in Etv1MLCCre mice (Figure 4H). Electron microscopy revealed no structural changes in the atria from both genotypes at baseline (Figure 4I). Atrial mRNA expression of the myocyte-specific myosin heavy polypeptide 6 (Myh6) gene did not differ between genotypes at baseline. Myh6 expression was significantly reduced in control atria after Ang II stimulation, whereas this downregulation was significantly attenuated in Etv1MLCCre atria (Figure 4J).

ETV1-Dependent Atrial Transcriptome

To determine the molecular basis of the protective effect of ETV1 ablation in atria, we performed RNA-seq in atria from control and Etv1MLCCre mice without or after Ang II stimulation (Figure 5A). Ang II stimulation induced gene expression changes of 2527 genes in control atria and 1293 genes in Etv1MLCCre atria (Online Figure XI; Online Table III). Eight hundred thirty genes were induced and 510 genes showed decreased expression after Ang II stimulation in control atria, although these genes were not significantly regulated in Etv1MLCCre atria (Figure 5A; Online Table IV). Gene ontology analysis of genes upregulated after Ang II stimulation in control atria and not regulated in Etv1MLCCre atria (Figure 5A, group 1) showed a significant enrichment for genes involved in cytoskeleton organization, cell-substrate adhesion, adherens junction, and proteinaceous extracellular matrix. Gene ontology analysis of the second group including genes downregulated after Ang II stimulation in control atria and no regulation in Etv1MLCCre atria (group 2) showed enrichment for genes involved in mitochondrial and metabolic pathways (Figure 5A). Expression of genes involved in mitochondrial function, Ca2+ handling, and ion channels was regulated by Ang II in control but not in ETV1-deficient atria (Figure 5B and 5C). These findings demonstrate...
that ablation of *Etv1* in cardiac myocytes protects atria from structural and molecular remodeling induced by Ang II.

**Comparison With Human AF**

For comparison of our mouse model with human permanent AF, we analyzed the atrial proteome and cardiac myocyte nuclear transcriptome (Figure 5D). In atria from patients with permanent AF,26 1237 proteins were differentially expressed when compared with control atria (Figure 5D). To determine, which of these proteins are expressed in atrial cardiac myocytes, we isolated cardiac myocyte nuclei and subjected these to RNA-seq, identifying 1099 genes which were expressed at 1 FPKM (fragments per kilobase per million mapped reads) or higher (Figure 5E). Differential protein expression in human...
Rommel et al  ETV1 and Atrial Remodeling

Figure 4. Etv1MLCCre mice are protected from structural remodeling after angiotensin II stimulation. A, Schematic diagram of the Etv1 gene targeting construct with 2 loxP sites (green arrowheads) that flank exon 11, encoding the ETS DNA-binding domain of the Etv1 protein. Targeted deletion of the Etv1 gene in cardiac myocytes is achieved by crossing the floxed Etv1 allele with MLC2a-Cre recombinase-expressing mice. B, Etv1 mRNA expression was significantly reduced by Etv1 gene targeting in cardiac myocytes but not in nonmyocytes (n=3–4). C, Cardiac sections of hematoxylin and eosin stained hearts from adult Etv1MLCCre and control animals (scale bar, 1 mm). D, Atrial weight/tibia length ratios after 2 weeks of angiotensin II (Ang II) stimulation (n=4–7). E, F, Atrial fibrosis determined by Sirius red staining in control and Etv1MLCCre atria without treatment (E) and after 2 weeks of Ang II stimulation (F; scale bar, 20 μm). G, Quantification of fibrosis (n=3–7). H, Expression levels of the fibroblast marker gene vimentin (Vim) in left atria at the basal state and after 2 weeks of Ang II stimulation. mRNA expression was measured by RT-qPCR. Ribosomal protein S29 (Rps29) was used as (Continued)
AF identified 155 proteins which were also regulated at the RNA level in mouse atria by Ang II/ETV1 (Figure 5F; Online Table V). Taken together, these findings indicate that our mouse model of Ang II/ETV1-dependent atrial remodeling is highly congruent with human permanent AF.

Chromatin Accessibility and Gene Expression in Mouse Atrial Cardiac Myocytes

To search for downstream genes specifically regulated by ETV1 in cardiac myocytes, we first established a method to isolate mouse atrial cardiac myocytes and nuclei for transcriptome analysis and for profiling of chromatin accessibility, respectively. Overall, 371 genes were differentially expressed in atrial versus ventricular cardiac myocytes (Online Figure XII). Two hundred two genes showed significantly higher expression levels in atrial versus ventricular myocytes, whereas 169 genes were preferentially expressed in ventricular myocytes (Online Figure XIIIB). Genes that were enriched in atrial cardiac myocytes were involved in processes like muscle adaptation, ventricular cardiac muscle tissue development, and positive regulation of muscle contraction (Online Figure XIIIC through XIIIE).

To determine the regulatory landscape of atrial cardiac myocytes, fluorescence-activated sorting of cardiac nuclei was used (Figure 6A through 6C). Chromatin accessibility was analyzed by ATAC-seq (assay for transposase-accessible chromatin sequencing). Ranking of genes according to their expression level showed a correlation of gene expression and chromatin accessibility at promoter regions (Figure 6D). Genes with very low expression levels (<1 FPKM) displayed no chromatin accessibility at promoter regions (Figure 6D).

In addition, we performed chromatin immunoprecipitation for the active histone modification H3K27ac followed by high-throughput sequencing (ChIP-seq) to identify putative active regulatory elements in atrial cardiac myocytes. Overall, 9340 regions with active signatures, including chromatin accessibility and enrichment of H3K27ac, were identified (Figure 6E and 6F). Two thousand thirty-five of these H3K27ac positive, ETV1 motif-containing accessible regions in mouse atrial cardiac myocytes (data set in Figure 6F). We identified 178 genes which were significantly regulated by Ang II stimulation in control atria, but not in ETV1-deficient atria and were also associated with active accessible regions containing ETV1-binding sites (Figure 7A; Online Table VI). Several of these genes have previously been associated with atrial arrhythmia or cardiac remodeling. To further validate these findings, the expression pattern of 18 candidates out of these 178 genes (Figure 7A) which have previously been associated with atrial arrhythmia was tested in ETV1-deficient (Figure 7B) and in ETV1-transgenic atria (Online Figure XIII) by RNA-seq and by quantitative RT-PCR, respectively. Ten genes showed opposing patterns of regulation in knockout and in transgenic atria (Figure 7B; Online Figure XIII through XVII). Ablation of ETV1 prevented the Ang II–mediated downregulation of potassium channels (Kcnh2, Kcnk3), genes involved in Ca2+ handling, and gap junction formation (Ryr2, Atp2a2, Jph2, Gja5) as well as the transcription factor Tbx5 (Figure 7B; Online Figure XIII). Moreover, ETV1 ablation prevented the Ang II–mediated upregulation of several genes (eg, Cib1, Bmp1, Ilk, Figure 7B and Online Figure XIII). Representative traces display genomic regions containing Cib1, Jph2, and Gja5 which show Ang II/ETV1-dependent gene expression changes and are associated with active accessible regions containing ETV1-binding sites in atrial cardiac myocytes (Figure 7C through 7E). Together, these results strongly support that ETV1 orchestrates the regulation of a transcriptional network that drives atrial remodeling.

Discussion

In this study, we identified an essential role of the E twenty-six (ETS) transcription factor ETV1 in Ang II–induced atrial remodeling. ETV1 was significantly upregulated in atrial tissue from patients with permanent AF and was highly expressed in atria versus ventricles. Cardiac myocyte-specific overexpression of ETV1 in mice induced atrial remodeling and arrhythmia, thrombus formation, and increased mortality. In contrast, ablation of ETV1 expression in cardiac myocytes protected mice from Ang II–induced atrial structural and molecular remodeling. Numerous genes which have previously been associated with AF or cardiac remodeling were regulated by Ang II in an ETV1-dependent manner and were associated with active ETV1-containing cis-regulatory elements in atrial cardiac myocytes. The ETV1-dependent transcriptome in mouse atria showed significant overlap with the human atrial proteome of patients with permanent AF. These results suggest that ETV1 may be an important mediator of arrhythmia-associated atrial remodeling.

Recently, ETV1 was identified as an important factor for the development of the fast conduction system consisting of atrial cardiac myocytes and the ventricular His-Purkinje network. The present mouse model of ETV1 ablation (Etv1MLCCre) shows similarities but also differences when compared with the model used by Shekhar et al. Shekhar’s group used a mouse model with constitutive deletion of exon 2 of the Etv1 gene by insertion of a nuclear localized β-galactosidase, thus resulting in a hypomorphic Etv1 allele in...
all cell types throughout development and postnatal life. This is in contrast with our mouse model, which relies on Cre-mediated ablation of *Etv1* expression in cardiac myocytes under control of the myosin light chain (*Myl7*, MLC2a-Cre) promoter starting at embryonic day E7.5. Constitutive ETV1 ablation led to lengthening of the P wave, PR interval, QRS
interval, and to bundle branch block in 30% of the KO mice at postnatal day P18. In contrast, cardiac myocyte-specific loss of ETV1 did not cause any obvious conduction deficits in adult mice (Online Figure VIII), suggesting that ablation of ETV1 by the MLC2a-Cre led to a more subtle phenotype when compared with the constitutive ablation. In addition, in fetal stages of mouse heart development, MLC2a expression is confined to the atrial working myocardium, the AV node, but it was undetectable in the bundle of His and the ventricular conduction system. Thus, regional expression of MLC2a-Cre during heart development in the present model may contribute to the specific phenotype. However, similar to our model, general loss of ETV1 did not affect ventricular structure and function.

ETV1 is a nuclear target of several intracellular signaling cascades. It was shown that ETV1 is activated by the Ras-MAPK pathway. In addition, other kinases downstream of the ERK (extracellular signal-regulated kinase), like the MSK1 (mitogen- and stress-activated protein kinase 1) or the 90-kDa RSK1 (ribosomal S6 kinase 1), phosphorylate, and
active ETV1 and its cofactors. Thus, ETV1 can be activated by signaling pathways initiated by GPCR that activate Gs or Gq/11 heterotrimeric G proteins, respectively.

The GPCR agonist Ang II plays an important role in atrial remodeling and fibrosis. To evaluate the ETV1-dependent effects on atrial remodeling, we treated ETV1-deficient mice...
and control mice with Ang II for 2 weeks. We found that ETV1-deficient mice were protected from Ang II–mediated atrial remodeling, whereas control animals showed a clear induction of atrial fibrosis. Previous work has shown that angiotensin-converting enzyme and ERK1/2 expression were increased in patients with AF. Furthermore, mice with cardiac Gtα overexpression develop spontaneous AF, atrial fibrosis, and dilatation. These results suggest that ETV1 operates as a transcriptional target downstream of Ang II–induced activation of MAPKs in atrial remodeling.

The pathophysiology of AF is complex and includes features like electrical remodeling, structural remodeling, autonomic nervous system changes, Ca2+ handling abnormalities, and a wide spectrum of molecular changes. To identify the molecular mechanism underlying the ETV1-dependent protection from Ang II–mediated atrial remodeling, we identified active cis-regulatory elements in mouse atrial cardiac myocytes using chromatin accessibility (ATAC-seq) and histone status (H3K27ac).

We found—among other genes—an upregulation of the calcium- and integrin-binding protein-1 (Cib1) gene in control atria stimulated with Ang II, although Cib1 was not regulated in ETV1-deficient atria. CIB1-deficient mice showed reduced cardiac hypertrophy, fibrosis, and cardiac dysfunction after pressure overload, whereas cardiac-specific overexpression of CIB1 augmented cardiac hypertrophy after pressure overload or calciuminin signaling. Moreover, CIB1 mRNA and protein expression was upregulated in atrial tissue from patients with AF. The integrin-linked kinase (Ilk) is upregulated in cardiac hypertrophy and mice expressing a constitutively active ILK exhibited hypertrophic remodeling. Interestingly, kinase-inactive ILK inhibited the prohypertrophic effect of Ang II on cardiac myocytes. Thus, Ang II–mediated ETV1-dependent upregulation of Cib1 and Ilk may contribute to hypertrophic remodeling of cardiac myocytes.

Besides the structural changes, electrical remodeling has been implicated in human AF: It has been shown that patients with mutations in the α-subunit of the voltage-gated potassium channel, encoded by the KCNH2 gene, present with higher incidence of AF. Our results reveal Ang II–mediated downregulation of Kcnh2, whereas ETV1 ablation prevented this downregulation. KCNH2 is responsible for the rapidly repolarizing potassium current (IKr) in atrial and ventricular cardiac myocytes and may contribute to action potential duration changes in AF.

Not only changes in ion channel expression but also gap junction remodeling, inducing impaired cell-cell coupling, contributes to conduction abnormalities. The gap junction protein α 5 (Gja5, connexin 40) was downregulated after Ang II stimulation in control atria but showed no regulation in ETV1-deficient atria. GJA5 is selectively expressed in atrial cardiac myocytes, and GJA5-deficient mice showed predispositions to arrhythmias. Moreover, human GJA5 gene variants were shown to be associated with AF.

Neither loss nor overexpression of Evtl elicited a primary ventricular phenotype. Differential chromatin accessibility between atrial and ventricular cardiac myocytes may be one important factor explaining the atrial specificity of the Evtl phenotype. Atrial enriched transcription factors like TBX5 may also contribute to this phenotype. In mouse atria, Tbx5 expression was repressed by Ang II in an ETV1-dependent manner. Interestingly, TBX5 mutations have been implicated in AF in human Genome-Wide Association Studies and loss of Tbx5 in adult mice caused atrial arrhythmia. Many Tbx5-dependent genes were also regulated by ETV1 in our study, including Gja5, Ryr2, Atp2a2, and Kcnh2. Interestingly, almost half of all open chromatin regions in atrial cardiac myocytes containing an ETV1-binding motif also showed TBX5-binding sites. Previously, a direct interaction of ETV1 with the T-box containing factor TPIT (T-box 19) has been demonstrated. Thus, cooperation between ETV1 and cardiac transcription factors may be important to shape the atrial cardiac myocyte transcriptome as it has been identified for other transcription factor pairs.

Several lines of evidence suggest that ETV1 may not only play a role in atrial remodeling in the mouse but also in human AF. First, ETV1 was upregulated in atrial biopsies from patients with permanent AF. Second, the ETV1-dependent transcriptome in mouse atria showed significant overlap with the human atrial proteome of patients with permanent AF. Third, a recent phenome-wide association study showed a strong association of an ETV1 SNP (single nucleotide polymorphism) with atrial conduction defects. Taken together, our results strongly support that ETV1 orchestrates a transcriptional network that drives atrial remodeling.

Acknowledgments

We thank Claudia Domisch and Birgit Scherer (University of Freiburg, Germany) for technical assistance. We acknowledge the support of the Freiburg Galaxy Team, Rolf Backofen and Björn Grüning (University of Freiburg, Germany), Larissa Fabritz (University of Birmingham, United Kingdom) for advice on ECG analysis, and Ali El-Armouche (Technische Universität Dresden) for atrial tissue samples. This study was supported by the Deutsche Forschungsgemeinschaft (SFB992 project B03, DFG HE 2073/5-1), the BIOSS Centre for Biological Signalling Studies, and PharmCompNet.

Sources of Funding

This study was supported by the Deutsche Forschungsgemeinschaft (SFB992 project B03, DFG HE 2073/5-1), the BIOSS Centre for Biological Signalling Studies, and PharmCompNet.

Disclosures

None.

References


